The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers

The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) is continuing its efforts through the Inflammatory Bowel Disease Genetics Consortium (IBDGC) to enhance understanding and treatment of IBD, a chronic and complex disease with no cure. The consortium has already identified over 300 genetic risk loci associated with various IBD subtypes and has contributed to uncovering the biological mechanisms behind the disease. Despite progress, critical gaps remain, particularly in diagnostic biomarkers and reliable predictors of outcomes such as disease remission, recurrence, and therapeutic responses. The IBDGC plans to utilize patient cohorts, biospecimens, and cutting-edge data science to comprehensively analyze genetics, clinical factors, and environmental influences to develop improved predictive tools aimed at enhancing medical care and enabling precision medicine for IBD patients. The initiative may encompass up to seven Genomic Research Centers, each potentially focusing on different research aspects, including participant enrollment, molecular analysis of biospecimens, and conducting bioinformatics and computational studies. This collaborative approach seeks to build on existing findings by integrating diverse datasets and advanced analytic methods to better characterize disease development and progression. Managed by the National Institutes of Health under the Department of Health and Human Services, the program is supported by a point of contact for coordination and further inquiries.